U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H21NO.C4H4O4
Molecular Weight 371.4269
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DIPHENHYDRAMINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=HTOPDYMCGZYYAS-BTJKTKAUSA-N
InChI=1S/C17H21NO.C4H4O4/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;5-3(6)1-2-4(7)8/h3-12,17H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula C17H21NO
Molecular Weight 255.3547
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Diphenhydramine is an antihistamine which is used in the combination with naproxen sodium for the relief of occasional sleeplessness when associated with minor aches and pains. Diphenhydramine has a role nighttime sleep-aid and naproxen sodium is a pain reliever. In addition, diphenhydramine used in relieving symptoms in patients with moderate-to-severe seasonal allergic rhinitis. Diphenhydramine acts as an antagonist of histamine H1 receptor. Besides, was shown potential to repurpose diphenhydramine as an anti-melanoma therapeutic agent, it induces melanoma cell apoptosis by suppressing STAT3/MCL-1 survival signaling pathway.

Originator

Curator's Comment: Diphenhydramine was discovered by George Rieveschl, in 1943 at the University of Cincinnati

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ALEVE PM

Approved Use

for relief of occasional sleeplessness when associated with minor aches and pains; helps you fall asleep and stay asleep

Launch Date

2014
Palliative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
93 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: UNKNOWN
age: ADOLESCENT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
667 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
887 ng × h/mL
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.2 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.5 h
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
18.3%
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unknown, 13 months
n = 1
Health Status: unknown
Age Group: 13 months
Sex: F
Population Size: 1
Sources:
Other AEs: QT interval prolonged...
Other AEs:
QT interval prolonged (1 patient)
Sources:
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 28 years
n = 1
Health Status: unhealthy
Condition: insomnia
Age Group: 28 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Liver injury, Vomiting...
AEs leading to
discontinuation/dose reduction:
Liver injury (1 patient)
Vomiting (1 patient)
Jaundice (1 patient)
Sources:
50 mg single, intravenous
Dose: 50 mg
Route: intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
n = 61
Health Status: unhealthy
Condition: Opioid dependence
Population Size: 61
Sources:
Other AEs: Hypertension...
Other AEs:
Hypertension (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
QT interval prolonged 1 patient
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unknown, 13 months
n = 1
Health Status: unknown
Age Group: 13 months
Sex: F
Population Size: 1
Sources:
Jaundice 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 28 years
n = 1
Health Status: unhealthy
Condition: insomnia
Age Group: 28 years
Sex: M
Population Size: 1
Sources:
Liver injury 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 28 years
n = 1
Health Status: unhealthy
Condition: insomnia
Age Group: 28 years
Sex: M
Population Size: 1
Sources:
Vomiting 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 28 years
n = 1
Health Status: unhealthy
Condition: insomnia
Age Group: 28 years
Sex: M
Population Size: 1
Sources:
Hypertension below serious, 5 patients
50 mg single, intravenous
Dose: 50 mg
Route: intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
n = 61
Health Status: unhealthy
Condition: Opioid dependence
Population Size: 61
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak [IC50 11 uM]
yes (co-administration study)
Comment: diphenhydramine coadministration significantly altered the pharmacokinetics, heart rate, systolic blood pressure, and peak acceleration response of metoprolol in extensive metabolizers but not in poor metabolizers
yes [IC50 15 uM]
yes [IC50 3.4 uM]
yes [IC50 695 uM]
yes [Ki 266.5 uM]
yes [Ki 87 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
major
minor
minor
minor
minor
no
no
no
weak
weak
weak
weak
weak
weak
weak
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

occasional sleeplessness: do not take more than directed; drink a full glass of water with each dose, adults and children 12 years and over: take 2 caplets at bedtime, do not take more than 2 caplets in 24 hours, if taken with food, this product may take longer to work
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In vitro, [14C] diphenhydramine was accumulated by a saturable, energy-requiring system in choroid plexus. The results show that diphenhydramine, unlike diazepam, is transported between blood, brain and cerebrospinal fluid, in part, by saturable, carrier-mediated transport processes at both the blood-brain and blood-cerebrospinal fluid barriers.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:16:41 GMT 2023
Edited
by admin
on Fri Dec 15 15:16:41 GMT 2023
Record UNII
54A11R7E1Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIPHENHYDRAMINE MALEATE
Common Name English
ETHANAMINE, 2-(DIPHENYLMETHOXY)-N,N-DIMETHYL-, (2Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
69013022
Created by admin on Fri Dec 15 15:16:41 GMT 2023 , Edited by admin on Fri Dec 15 15:16:41 GMT 2023
PRIMARY
CAS
114402-66-3
Created by admin on Fri Dec 15 15:16:41 GMT 2023 , Edited by admin on Fri Dec 15 15:16:41 GMT 2023
PRIMARY
FDA UNII
54A11R7E1Y
Created by admin on Fri Dec 15 15:16:41 GMT 2023 , Edited by admin on Fri Dec 15 15:16:41 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY